Tarlatamab for advanced rare cancers outside the lung
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been treated with a type of chemotherapy containing platinum, and it stopped working or the cancer came back.
- Your cancer is a rare type called extrapulmonary small cell carcinoma or neuroendocrine carcinoma, found in areas like the gut, bladder, or head and neck.
- You have at least one measurable tumor by a standard scan (CT or MRI) within the past 4 weeks.
- You are generally healthy enough for daily activities (performance status 0 or 1) and are at least 18 years old.
- You can provide a tissue sample from a past biopsy or agree to have a new biopsy before starting treatment.
- If you have had brain metastases that were treated, they must be stable and you must be off steroids for at least a week.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
This trial tests a new drug called tarlatamab for people with extensive-stage small-cell lung cancer who are too unwell for standard treatments. It aims to see if the drug can help shrink tumors and improve outcomes.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
This trial tests a new drug, Tarlatamab, for women whose gynecological neuroendocrine cancer has come back or spread. The drug targets a protein on cancer cells to help the immune system attack them. The study aims to see if it can shrink tumors and slow the disease.
Hear when a new Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.